Notable Downgrades: BioMarin Pharmaceutical (BMRN), Finisar (FNSR), Oracle (ORCL), Zoe’s Kitchen (ZOES)

Analysts at Robert W. Baird are out with a report today downgrading shares of BioMarin Pharmaceutical Inc. (BMRN) with a ‘Neutral‘ from ‘Outperform‘ rating. The firm however, raised its price target for the company to $133 from $125.

BMRN shares recently lost $1.21 to $137.45. In the past 52 weeks, shares of San Rafael, California-based firm have traded between a low of $55.36 and a high of $140.49. Shares are up 121.29% year-over-year and 53.38% year-to-date.

Analysts at Raymond James downgraded Finisar Corp. (FNSR) from ‘Strong Buy‘ to ‘Outperform‘ in a research report issued to clients on Friday.

On valuation measures, Finisar Corp. stock it’s trading at a forward P/E multiple of 15.73x, and at a multiple of 61.94x this year’s estimated earnings. The t-12-month revenue at Finisar Corp. is $1.24 billion. FNSR ‘s ROE for the same period is 3.23%.

Shares of the $2.06 billion market cap company are up 11.64% year-over-year and 14.12% year-to-date.

Finisar Corp., currently with a median Wall Street price target of $25.00 and a high target of $27.00, dropped $2.33 to $19.82 in recent trading.

The chart below shows where the equity has traded over the past 52-weeks.

UBS analysts lowered this morning their Oracle Corporation (ORCL) price target to $46 from $48. Shares have traded today between $42.01 and $43.10 with the price of the stock fluctuating between $35.82 to $46.71 over the last 52 weeks.

Oracle Corp. shares are currently changing hands at 17.58x this year’s forecasted earnings, compared to the industry’s 22.72x earnings multiple. Ticker has a t-12 price/sales ratio of 4.81. EPS for the same period registers at $2.39.

Shares of ORCL have lost $0.66 to $42.08 in midday trading on Friday, giving it a market cap of roughly $184 billion. The stock traded as high as $46.71 in December 24, 2014.

Zoe’s Kitchen, Inc. (ZOES) had its rating lowered from ‘Overweight‘ to ‘Neutral‘ by analysts at Piper Jaffray on Friday. Currently there are 3 analysts that rate ZOES a ‘Buy‘, no analysts rate it a ‘Sell‘, while 5 rate it a ‘Hold‘.

ZOES was down $2.43 at $39.62 in midday trade, moving within a 52-week range of $27.09 to $42.92. The name, valued at $765.30 million, opened at $39.00.

On valuation measures, Zoe’s Kitchen Inc. shares are currently priced at 1,132.00x this year’s forecasted earnings. Ticker has a t-12 price/sales ratio of 4.31. EPS for the same period registers at $0.04.

Be the first to comment

Leave a Reply

Your email address will not be published.


*